Dyne Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DYNE THERAPEUTICS, INC. | ||
| Date: February 27, 2025 | By: | /s/ John G. Cox |
|---|---|---|
| John G. Cox | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ John G. Cox | President, Chief Executive Officer and Director (principal executive officer) | February 27, 2025 |
| John G. Cox | ||
| /s/ Richard Scalzo | Senior Vice President, Head of Finance and Administration (principal financial and accounting officer) | February 27, 2025 |
| Richard Scalzo | ||
| /s/ Jason Rhodes | Director and Chairman of the Board | February 27, 2025 |
| Jason Rhodes | ||
| /s/ Ed Hurwitz | Director | February 27, 2025 |
| Ed Hurwitz | ||
| /s/ Carlo Incerti, M.D. | Director | February 27, 2025 |
| Carlo Incerti, M.D. | ||
| /s/ Dirk Kersten | Director | February 27, 2025 |
| Dirk Kersten | ||
| /s/ David Lubner | Director | February 27, 2025 |
| David Lubner | ||
| /s/ Catherine Stehman-Breen, M.D. | Director | February 27, 2025 |
| Catherine Stehman-Breen, M.D. | ||
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.